Designing early detection programs for ovarian cancer

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 16-18

  Urban, N ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CA125; HE4; Mesothelin; MMP7; Ovarian cancer; Screening; Symptoms index

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TRANSVAGINAL ECHOGRAPHY;

EID: 84869204977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr472     Document Type: Conference Paper

References (11)

1. A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women. 2010; http://clinicaltrials.gov/ct2/show/NCT01121640 (date last accessed 6 June 2011).
2. McIntosh M, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 2003; 4: 27-40.
3. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-340.
4. Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113: 775-782.
5. Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228.e1-6.
6. Montagnana M, Lippi G, Ruzzenente O et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009; 23: 331-335.
7. Abdel-Azeez HA, Labib HA, Sharaf SM et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010; 11: 111-116.
8. Anderson GL, McIntosh MW, Wu L et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010; 102: 26-38.
9. Cramer DW, Bast RC Jr, Berg CD et al. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res 2011; 4: 365-374.
10. Zhu CS, Pinsky PF, Cramer DW et al. for the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011; 4: 375-383.
11. Andersen M, Goff B, Lowe K et al. Use of a symptom index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol 2010; 116: 378-383.